Search

US-12616849-B2 - Sunglass lens and sunglass optics for ocular photo-bio-stimulation

US12616849B2US 12616849 B2US12616849 B2US 12616849B2US-12616849-B2

Abstract

A lens or optic, including a sunglass lens or sunglass optic, providing ocular photo-bio-stimulation therapy.

Inventors

  • Ronald Blum
  • Jack Loeb
  • Anita Broach

Assignees

  • NeuroRays, LLC

Dates

Publication Date
20260505
Application Date
20241118

Claims (18)

  1. 1 . A sunglass lens or sunglass optic, wherein the sunglass lens or sunglass optic provides light transmission of 40% or more of ocular photo-bio-stimulation light measured within a light wavelength range of 450 nm-510 nm to an eye of a wearer of the sunglass lens or sunglass optic, wherein a light transmission curve spectra of the sunglass lens or sunglass optic when superimposed on or over a light absorption curve spectra of melanopsin and rhodopsin covers 50% or more of the melanopsin and rhodopsin absorption curve spectra, wherein a visible light transmission (VLT) of the sunglass lens or sunglass optic is 30% or less, wherein the sunglass lens or sunglass optic is designed to transmit an amount of red light, yellow light, and green light, sufficient to pass a regulatory traffic signal test or standard for color transmission of red light, yellow light, and green light, and wherein a visible light transmission peak of the sunglass lens or sunglass optic does not exceed 40% within a light wavelength range of 600 nm-750 nm.
  2. 2 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic is supported or housed by at least one of: eyewear, fit over eyewear, disposable eyewear, a helmet, augmented reality eyewear, virtual reality eyewear, mixed reality eyewear, modified reality eyewear, a contact lens(es), an intraocular lens(es), a corneal implant, or sunglasses.
  3. 3 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic transmits light having an intensity of 350 lux or greater.
  4. 4 . The sunglass lens or sunglass optic of claim 1 , wherein the ocular photo-bio-stimulation light includes the light wavelength range of 450 nm-510 nm, and wherein the ocular photo-bio-stimulation light including the light wavelength range of 450 nm-510 nm stimulates a production of dopamine in the eye of the wearer.
  5. 5 . The sunglass lens or sunglass optic of claim 1 , wherein the ocular photo-bio-stimulation light includes the light wavelength range of 450 nm-510 nm, and wherein the ocular photo-bio-stimulation light including the light wavelength rage of 450 nm-510 nm stimulates a production of dopamine or serotonin in a brain of the wearer.
  6. 6 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic comprises a surface cast layer that filters light.
  7. 7 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic comprises a lens matrix or optics matrix that: filters or blocks ultraviolet light, is imbibed with a dye or light absorber, or combinations thereof.
  8. 8 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic comprises one or more of: an interference filter, an absorption filter, a light absorber, dye, a neutral density filter, a bandpass filter, a notch filter, or a selective blue light filter.
  9. 9 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic comprises an optical power, including plano optical power.
  10. 10 . The sunglass lens or sunglass optic of claim 1 , wherein a filtered tint of the sunglass lens or sunglass optic is fixed or constant.
  11. 11 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic allows for light transmission of 400 lux or more within the light wavelength range of 450 nm-510 nm when worn in sunlight throughout a same day from morning daylight until early sunset of the same day.
  12. 12 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic transmits light through the sunglass lens or sunglass optic within the range of 450 nm-510 nm having a light intensity of 350 lux or greater.
  13. 13 . The sunglass lens or sunglass optic of claim 1 , wherein the light transmission of 40% or more ocular photo-bio-stimulation light within the range of 450 nm-510 nm stimulates production of dopamine in the eye of the wearer or a brain of the wearer.
  14. 14 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic comprises an optical power.
  15. 15 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic is classified as a category 2 sunglass lens or sunglass optic.
  16. 16 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic is classified as a category 3 sunglass lens or sunglass optic.
  17. 17 . The sunglass lens or sunglass optic of claim 1 , wherein light transmitted through the sunglass lens or sunglass optic has a light intensity of 350 lux or greater after transmission through the sunglass lens or sunglass optic.
  18. 18 . The sunglass lens or sunglass optic of claim 1 , wherein the sunglass lens or sunglass optic comprises plano optical power.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS The present application relies on the disclosures of and claims priority to and the benefit of the filing dates of the following U.S. patent applications: U.S. Appl. No. 63/600,139, filed Nov. 17, 2023, titled Enhanced Neuro-Light TherapyU.S. Appl. No. 63/603,258, filed Nov. 28, 2023, titled Optimized Neuro-Light TherapyU.S. Appl. No. 63/609,306, filed Dec. 12, 2023, titled Neuro-Light Therapy ImprovedU.S. Appl. No. 63/617,363, filed Jan. 3, 2024, titled Neuro-Light Therapy OptimizedU.S. Appl. No. 63/623,253, filed Jan. 20, 2024, titled Neuro-Light Therapy Further OptimizedU.S. Appl. No. 63/627,703, filed Jan. 31, 2024, titled Neuro-Light Optogenetic TherapyU.S. Appl. No. 63/550,852, filed Feb. 7, 2024, titled Enhanced Neuro-Light Optogenetic TherapyU.S. Appl. No. 63/553,226, filed Feb. 14, 2024, titled Neuro-Light Optogenetic Therapy EnhancedU.S. Appl. No. 63/553,693, filed Feb. 15, 2024, titled Enhanced Neuro-Light Optogenetic TherapyU.S. Appl. No. 63/561,266, filed Mar. 4, 2024, titled Ocular Neuro-Light TherapyU.S. Appl. No. 63/569,005, filed Mar. 22, 2024, titled Ocular Neuro-Light Therapy ImprovedU.S. Appl. No. 63/639,892, filed Apr. 29, 2024, titled Ocular Optogenetic Neuro TherapyU.S. Appl. No. 63/648,098, filed May 15, 2024, titled Ocular Optogenetic TherapyU.S. Appl. No. 63/654,566, filed May 31, 2024, titled Optogenetic Lens DesignsU.S. Appl. No. 63/671,237, filed Jul. 14, 2024, titled XR Optogenetic Stimulation of the Human Eye and Sunglasses Allowing Dopamine ProductionU.S. Appl. No. 63/673,746, filed Jul. 21, 2024, titled Enhanced XR Optogenetic Stimulation of the Human Eye and Sunglasses Allowing Dopamine ProductionU.S. Appl. No. 63/674,219, filed Jul. 22, 2024, titled Advanced XR Optogenetic Stimulation of the Human Eye and Sunglasses Allowing Dopamine ProductionU.S. Appl. No. 63/676,855, filed Jul. 29, 2024, titled XR Optogenetic StimulationU.S. Appl. No. 63/684,509, filed Aug. 19, 2024, titled Refined Optogenetic Lens DesignsU.S. application Ser. No. 18/827,782, filed Sep. 8, 2024, titled Ocular Photo-Bio-Stimulation OpticsU.S. application Ser. No. 18/827,786, filed Sep. 8, 2024, titled Ocular Photo-Bio-Stimulation OpticsU.S. Appl. No. 63/697,560, filed Sep. 22, 2024, titled Filtering Eyewear and Optics for Ocular Photo-Bio-StimulationU.S. application Ser. No. 18/914,202, filed Oct. 13, 2024, titled Filtering Eyewear and Optics for Ocular Photo-Bio-StimulationU.S. application Ser. No. 18/928,126, filed Oct. 27, 2024, titled Filtering Eyewear and Optics for Ocular Photo-Bio-StimulationU.S. application Ser. Nos. 18/827,782, and 18/827,786 rely on the disclosures of and claim priority to and the benefit of the filing dates of U.S. Appl. No. 63/537,021, filed Sep. 7, 2023, titled Device Providing Blue Light for Alertness and Red Light for Calming, U.S. Appl. No. 63/540,090, filed Sep. 24, 2023, titled Enhanced Device Providing Blue Light for Alertness and Red Light for Calming, and U.S. Appl. No. 63/541,243, filed Sep. 28, 2023, titled Device Providing Blue Light Alertness and/or Red Light Calming, U.S. Appl. No. 63/546,848, filed Nov. 1, 2023, titled Improved Eyewear or Optic Providing Blue Light Alertness, Myopia Control, Green Light Pain Relief, and Red-Light Calming, and U.S. Appl. No. 63/548,204, filed Nov. 12, 2023, titled Neuro-Light Therapy. The disclosures of those applications are hereby incorporated by reference herein in their entireties. BACKGROUND OF THE INVENTION Field of the Invention The current invention relates, in part, to ocular photo-bio-stimulation therapy, a biological technique to control or influence the activity of neurons or other cell types in, on or about the eye with light. As used herein ocular photo-bio-stimulation is an umbrella category of which photobiomodulation, optogenetics and phototherapy are forms thereof. The current invention relates, in part, to photobiomodulation therapy, which includes the utilization of non-ionizing electromagnetic energy to trigger photochemical changes within cellular structures. The current invention relates, in part, to optogenetics. Optogenetics is a biological technique to control the activity of neurons or other cell types with light. The current invention relates, in part, to phototherapy, also known as light therapy or bright light therapy, which is a treatment that uses controlled exposure to artificial or natural light to treat medical conditions. A description of the anatomy of the eye will help understand the invention described herein. The Eye's Retinal Layer In reference to FIG. 1, retinal cones are photoreceptor cells in the retina that give humans color vision and help them see fine details. They are cone-shaped, with a pointed tip at the top and a circular bottom, and are concentrated in the center of the retina, in an area called the macula, the center of which is called the fovea. There are ˜6M cones. In further reference to FIG. 1, retinal Rods make up more than 95% of